

# CURRICULUM VITAE

*MICHAEL A. NOVAK, MD*

**OFFICE ADDRESSES** Retina Associates of Cleveland, Inc.  
690 White Pond Drive, Suite 120; Akron, Ohio 44320  
3401 Enterprise Parkway, Suite 300; Beachwood, Ohio 44122  
4690 Munson Street NW; Canton, Ohio 44718  
340 Oxford Street, Suite 210; Dover, Ohio 44622  
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052  
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060  
15299 Bagley Road, Suite 200; Middleburg Heights, Ohio 44130  
17534 Royalton Road, Suite 201; Strongsville, Ohio 44136  
170 North Road NE; Warren, Ohio 44483  
4350 Crocker Road, Suite 200; Westlake, Ohio 44145  
5390 Belmont Avenue; Youngstown, Ohio 44505

**TELEPHONE** 216-831-5700

**WEBSITE** [www.retina-doctors.com](http://www.retina-doctors.com)

## EDUCATION

*College* Adelbert College, Case Western Reserve University  
Cleveland, Ohio  
1969–1973, BA

*Medical School* Case Western Reserve University School of Medicine,  
Cleveland, Ohio  
1973–1977, MD

## POSTGRADUATE TRAINING

*Internship* Medicine  
University Hospitals of Cleveland  
Cleveland, Ohio  
1977–1978

*Residency* Ophthalmology  
The Wilmer Ophthalmological Institute of the Johns Hopkins Hospital  
The Johns Hopkins University School of Medicine  
Baltimore, Maryland  
1978–1981

*Fellowship*                      Retina and Vitreous Diseases and Surgery  
The Wilmer Ophthalmological Institute of the Johns Hopkins Hospital  
The Johns Hopkins University School of Medicine  
Baltimore, Maryland  
1981–1982

Chief Resident, Assistant Chief of Service  
The Wilmer Ophthalmological Institute of the Johns Hopkins Hospital  
The Johns Hopkins University School of Medicine  
Baltimore, Maryland  
1982–1983

#### LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio  
Diplomate, American Board of Ophthalmology, 1982

#### PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 1983–  
Practice limited to retinal diseases and surgery. Associates: Lawrence J. Singerman, MD;  
Hernando Zegarra, MD; Z. Nicholas Zakov, MD; Scott D. Pendergast, MD; David G.  
Miller, MD; Joseph M. Coney, MD; Jerome P. Schartman, MD; Llewelyn J. Rao, MD;  
Arnold F. Nothnagel, DO; Shawn A. Lewis, MD; Sean M. Platt, MD

#### ACADEMIC APPOINTMENTS

Assistant Clinical Professor of Ophthalmology  
Case Western Reserve University School of Medicine  
1983–2002

Instructor in Ophthalmology  
The Johns Hopkins University School of Medicine  
1982–1983

#### PROFESSIONAL SOCIETIES AND COMMITTEES

Diabetes Education Committee  
Hillcrest Hospital  
1991

Diabetes Advisory Committee  
International Diabetes Center  
Marymount Hospital  
1988

Quality Assurance Committee  
Department of Surgery  
St. Luke's Hospital  
1986, 1987, 1988

Library Committee  
St. Luke's Hospital  
1986, 1987

Investigational Review Board  
Hillcrest Hospital  
1985, 1986

## HONORS AND AWARDS

*Best Doctors in America*, 2011-2018; *Top Doctors*, 2015

Member, Phi Beta Kappa

Honor Award  
American Academy of Ophthalmology, 1992

Teaching Award  
Mount Sinai Medical Center of Cleveland  
Ophthalmology Residents Program, 1986, 1987

Teaching Award  
St. Luke's Hospital of Cleveland  
Ophthalmology Residents Program, 1985

Co-recipient, First Annual Outstanding Teacher Award  
Case Western Reserve University Hospitals  
Ophthalmology Residents Program, 1985

## MEMBERSHIPS

American Academy of Ophthalmology  
American Society of Retinal Specialists (formerly the Vitreous Society)  
American Medical Association  
Association for Research in Vision and Ophthalmology  
Cleveland Academy of Medicine

Cleveland Ophthalmological Society  
Diabetes Association of Greater Cleveland  
Member, Board of Trustees, 1988  
European VitreoRetinal Society  
Macula Society  
Ohio Medical Association  
Ohio Ophthalmological Society  
Member, Board of Governors, 1986–1988  
Retina Society  
Wilmer Residents Association

## HOSPITAL & ASC AFFILIATIONS

Cleveland Eye and Laser Surgery Center; Cleveland, Ohio  
Brainard Surgery Center; Cleveland, Ohio  
Akron General Medical Center; Akron, Ohio  
Summa Health; Akron, Ohio  
Lippy Surgery Center; Warren, Ohio  
Surgery Center of Canfield; Canfield, Ohio

## TEACHING ACTIVITIES

Ophthalmology residents, Case Western Reserve University

- Retina Clinic and surgery supervision, MetroHealth Medical Center, 1983 – (2-3 hours every other week)
- Clinical Conferences and Fluorescein Angiography Conferences, 1983 – (5-8 hours per year)

Ophthalmology residents, St. Luke's Medical Center of Cleveland

- General Clinic and Retina Clinic, 1983–1986
- Lectures and Clinical Conferences, 1983–1999 (12 hours per year)

Ophthalmology residents, Mount Sinai Medical Center of Cleveland

- Retina Clinic and surgery supervision, 1983–2000 (3-4 hours every other week)
- Lectures and Clinical Conferences, 1983–2000 (4-6 hours per year)

American Academy of Ophthalmology Meeting Annual Courses:

- Complications of vitreous surgery, 1982 (3 hours)
- Evaluation and management of proliferative retinopathies, 1983–1990
- Management of rubeosis iridis and neovascular glaucoma, 1990, 1991
- Guidelines for Evaluating and Treating Choroidal Neovascularization, 1998, 1999

American College of Surgeons Clinical Congress

- Postgraduate course: Update on ophthalmic laser surgery – central serous chorioretinopathy, 1985

**RESEARCH ACTIVITIES***NIH-funded Grants*

*DRCRnet Protocol W. Intravitreal anti-vascular endothelial growth factor treatment for prevention of vision threatening diabetic retinopathy in eyes at high risk*

Principal investigator, 2016–

*DRCRnet Protocol S. Prompt panretinal photocoagulation versus ranibizumab+deferred panretinal photocoagulation for proliferative diabetic retinopathy*

Principal investigator, 2012–2017

*DRCRnet Protocol M. Effect of diabetes education during retinal ophthalmology visits on diabetes control*

Principal investigator, 2011–2015

*Home vision monitoring in AREDS2 for progression to neovascular age-related macular degeneration*

Principal Investigator, 2011–2013

*DRCRnet Protocol N. Evaluation of intravitreal ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy*

Principal Investigator, 2010–2012

*DRCRnet Protocol O. Comparison of time-domain OCT and spectral domain OCT retinal thickness measurement in diabetic macular edema*

Principal Investigator, 2009–2010

*DRCRnet Protocol I. Intravitreal ranibizumab or triamcinolone acetonide in combination with laser photocoagulation for diabetic macular edema*

Principal Investigator, 2007–2014

*Age-Related Eye Disease Study 2*

Principal investigator, 2006–2012

*DRCRnet Protocol V. Treatment for central involved diabetic macular edema in eyes with very good visual acuity*

Co-investigator, 2014–

*DRCRnet Protocol U. Short-term evaluation of combination corticosteroid+anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes*

Co-investigator, 2014–

*Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2)*

Co-investigator, 2014–

*DRCRnet: Genes in Diabetic Retinopathy Project*

Co-investigator, 2012–

*DRCRnet Protocol R. Phase II evaluation of topical NSAIDS on eyes with non-central involved DME*

Co-investigator, 2011–2013

*Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial (CATT)*

Co-investigator, 2008–2012

*DRCRnet Protocol K. Course of response to focal photocoagulation for diabetic macular edema*

Co-investigator, 2007–2008

*DRCRnet Protocol H. A Phase 2 evaluation of anti-VEGF therapy for diabetic macular edema: bevacizumab (Avastin)*

Co-investigator, 2006–2008

*DRCRnet Protocol E. A pilot study of peribulbar triamcinolone acetonide for diabetic macular edema*

Co-investigator, 2005–2007

*Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study*

Co-investigator, 2004–2009

*Diabetic Retinopathy Clinical Research Network (DRCRnet) Protocol #1A. A pilot study of laser photocoagulation for diabetic macular edema*

Co-investigator, 2004–2007

*DRCRnet Protocol B. A randomized trial comparing intravitreal triamcinolone acetonide and laser photocoagulation for diabetic macular edema*

Co-investigator, 2004–2007

*Family Investigation of Nephropathy and Diabetes (FIND)*

Co-investigator/Study Ophthalmologist, 2003–

*Complications of Age-related Macular Degeneration Prevention Trial (CAPT)*

Co-investigator, 1998–2007

*Submacular Surgery Trials*

Co-investigator, 1995–2004

*Choroidal Neovascularization Prevention Trial – Pilot Study*

Co-investigator, 1995–2001

*Endophthalmitis Vitrectomy Study*

Co-investigator, 1988–1994

*Vitrectomy for Prevention of Macular Holes Study*

Co-investigator, 1988–1994

*Collaborative Ocular Melanoma Study (COMS)*

Following and Enuclating Ophthalmologist, 1987–2003

*Diabetes Control and Complications Trial*

Ophthalmologist, 1983–1994

*Krypton Argon Regression of Neovascularization Study*

Co-investigator, 1983–1993

*Macular Photocoagulation Study*

Co-investigator, 1983–1993

***Other National Clinical Trials***

*OMEGA: A randomized, double-masked, dose-ranging, multi-center, phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration*

Principal investigator, 2006–2009

*A multi-center, double-masked, randomized, vehicle-controlled, parallel group evaluation of the safety and efficacy of OT-551 ophthalmic solution to prevent formation or delay progression of nuclear cataract formation in post-vitrectomy patients*

Principal investigator, 2005–2007

*Visudyne Patient Registry*

Principal investigator, 2005–2007

*Randomized, double masked, uncontrolled, multicenter phase I/II study to evaluate safety and tolerability of PAN-90806 eye drops, suspension in treatment-naïve participants with neovascular age-related macular degeneration (AMD)*

Co-investigator, 2018–

*Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (YOSEMITE)*

Co-investigator, 2018–

*Two-year, three-arm, randomized, double-masked, multicenter, phase iii study assessing the efficacy and safety of brolicizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema (KESTREL)*

Co-investigator, 2018–

*Phase 2b randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura™ (anti-c5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration*

Co-investigator, 2018–

*Phase III randomised, double-masked, parallel group, multicentre study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and lucentis® in subjects with neovascular age-related macular degeneration*

Co-investigator, 2018–

*Phase 2 double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15 mg once daily or 15 mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (TIME-2b study)*

Co-investigator, 2017–

*Phase III multicenter randomized, sham controlled, study to determine the safety and efficacy of Renexus® in macular telangiectasia type 2 (NTMT-03-A)*

Co-investigator, 2017–

*Efficacy and safety study of squalamine ophthalmic solution in subjects with neovascular AMD (MAKO)*

Co-investigator, 2016–

*Randomized, double-masked, placebo-controlled, dose- finding, non-inferiority study of X-82 plus prn intravitreal (IVT) anti-VEGF compared to prn IVT anti-VEGF monotherapy in neovascular AMD*

Co-investigator, 2016–2018

*Phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy (GA)*

Co-investigator, 2015–2018

*Phase III double masked study of safety and efficacy of abicipar pegol in patients with neovascular age-related macular degeneration*

Co-investigator, 2015–

*Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration*

Co-investigator, 2015–2018



*Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration (PROXIMA)*

Co-investigator, 2015–2018

*Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration*

Co-investigator, 2015–2017

*An 18-month Phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)*

Co-investigator, 2015–2017

*A study of lampalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy (EXPOSURE)*

Co-investigator, 2015–2017

*LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration*

Co-investigator, 2015–2016

*A study investigating the efficacy and safety of lampalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (CHROMA)*

Co-investigator, 2014–2018

*Phase 2, multi-center study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist with ranibizumab in adults with diabetic macular edema*

Co-investigator, 2014–2015

*Phase 2 multicenter randomized clinical trial of ciliary neurotrophic factor (CNTF) for macular telangiectasia type 2 (MacTel)*

Co-investigator, 2013–

*Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration*

Co-investigator, 2013–2017

*Phase 2b/3 multicenter, randomized, double-masked, dose-ranging study comparing the efficacy and safety of emixustat hydrochloride (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry age-related macular degeneration (SEATTLE)*

Co-investigator, 2013–2016

*Prospective, randomized, double-masked, multicenter, two-arm study comparing the efficacy and safety of ESBA1008 versus Eylea® in subjects with exudative age-related macular degeneration (OSPREY)*

Co-investigator, 2013–2014

*A multicenter, open-label extension study to evaluate the long-term safety and tolerability of FCFD4514S in patients with geographic atrophy Protocol (OLEi, GX29198)*

Principal Investigator, 2012–2018

*A multicenter, randomized, sham-control, proof-of-concept study of intravitreal LFG316 in patients with geographic atrophy associated with age-related macular degeneration*

Co-investigator, 2012–2015

*Efficacy and safety of squalamine lactate eye drops in subjects with neovascular (wet) age-related macular degeneration*

Co-investigator, 2012–2015

*Ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS)*

Co-investigator, 2012–2014

*Safety and tolerability of intravenous LFG316 in wet age-related macular degeneration*

Co-investigator, 2012–2013

*Single and repeat dose study of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration*

Co-investigator, 2012

*A study of safety, tolerability, and evidence of activity of FCFD4514S administered monthly or every other month to patients with geographic atrophy*

Co-investigator, 2011–2013

*Phase 1 multicenter open-label safety and tolerability clinical trial of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia Type 2 (MacTel)*

Co-investigator, 2011–2016

*Multicenter, 2 stage (open label, dose escalation, followed by masked, randomized) single dose study of the safety and efficacy of AGN-208397 in patients with macular edema (ME) associated with retinal vein occlusion (RVO)*

Co-investigator, 2011–2012

*Phase 2b dose-ranging study of pazopanib eye drops versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration*

Co-investigator, 2010–2011

*Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration*

Co-investigator, 2010–2011

*Phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration (HARBOR) (Genentech)*

Co-investigator, 2009–2012

*Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion*

Co-investigator, 2009–2012

*Geographic Atrophy Treatment Evaluation (GATE) Study*

Co-investigator, 2009–2012

*Phase 1a, multicenter, open-label, single-dose, dose-escalation study of the safety, tolerability, pharmacokinetics, and immunogenicity of intravitreal injections of FCFD4514S in patients with geographic atrophy*

Co-investigator, 2009–2010

*Phase II, randomized, double-masked, placebo-controlled, add-on study to assess the efficacy of oral aliskiren 300 mg one daily for diabetic macular edema*

Co-investigator, 2009–2010

*Phase 1, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of Volociximab ( $\alpha 5\beta 1$  integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD (Ophthotech 3000)*

Co-investigator, 2008–2011

*Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with DME secondary to diabetic retinopathy*

Co-investigator, 2008–2010

*Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy*

Co-investigator, 2008–2010

*Anecortave acetate for treatment of steroid-induced intraocular pressure (IOP) elevation*

Co-investigator, 2008–2010

*Natural History of Geographic Atrophy Progression (GAP) Study*

Co-investigator, 2008–2009

*Safety and efficacy of 700ug dexamethasone posterior segment drug delivery system (DEXDDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of diffuse macular edema (DME)*

Co-investigator, 2008–2009

*A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)*

Co-investigator, 2007–2012

*A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema*

Co-investigator, 2007–2009

*Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis®) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)*

Co-investigator, 2007–2009

*Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC) study comparing preferential hyperacuity perimetry (PHP) with supervised Amsler grid in detecting AMD for earlier treatment in high-risk fellow eyes (Johns Hopkins)*

Co-investigator, 2007–2009

*A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin for Vitreous Injection III) Trial*

Co-investigator, 2007–2008

*Small Interfering RNA In Macular Degeneration Study (SIRIUS): A 2 year, multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN211745 in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration*

Co-investigator, 2007–2008

*COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)*

Co-investigator, 2007–2008

*Phase I, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD*

Co-investigator, 2007

*Denali: a 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne® photodynamic therapy administered in conjunction with ranibizumab (Lucentis®) versus ranibizumab (Lucentis®) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration*

Co-investigator, 2007

*Sirion Phase II randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of geographic atrophy in age-related macular degeneration*

Co-investigator, 2006–2010

*Macugen (pegaptanib sodium) for pathological myopia complicated by subfoveal choroidal neovascularization*

Co-investigator, 2006–2010

*Macugen (pegaptanib sodium) for angioid streaks complicated by choroidal neovascular membrane*

Co-investigator, 2006–2010

*Study of the efficacy and safety of intravitreal injection of Macugen for neovascular lesions of AMD with recent onset*

Co-investigator, 2006–2008

*A Phase IIIB, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization secondary to age-related macular degeneration (SAILOR)*

Co-investigator, 2006–2007

*Phase IV, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement (Eyeteach 1023)*

Co-investigator, 2006

*Natural history and genetics study of macular telangiectasia (MacTel)*

Co-investigator, 2005–

*The effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography*

Co-investigator, 2005–2011

*Interval Dose Evaluation of Anecortave Acetate (IDEAA)*

Co-investigator, 2005–2008

*A 6-month, Phase III, multicenter, masked, randomized, sham-controlled trial (with 6-month open-label extension) to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following branch retinal vein occlusion or central retinal vein occlusion*

Co-investigator, 2005–2007

*A 3-year, Phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with diabetic macular edema*

Co-investigator, 2005–2007

*RNAi Assessment of Cand5 in Diabetic Macular Edema (RACE)*

Co-investigator, 2005–2007

*Cand5 Anti-VEGF RNAi Evaluation (CARE)*

Co-investigator, 2005–2007

*A Phase 4, randomized, active controlled, double masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen® given every 6 weeks for 102 weeks plus sham photodynamic therapy (PDT), to Macugen plus PDT® with Visudyne in subjects with predominantly classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) (Eyeteck 1012)*

Co-investigator, 2005–2007

*Phase IV study of daily dosing (vs. previous “on demand”) of Cialis vs. Viagra vs. placebo and its effect on visual functioning in healthy males or those with mild erectile dysfunction*

Co-investigator, 2005–2006

*Veritas: A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne®) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne® plus intravitreal pegaptanib (Macugen®) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration*

Co-investigator, 2005–2006

*Protocol A43221001: A Phase 1 / 2 randomized, masked, placebo-controlled, single and multiple-dose, sequential dose escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration*

Co-investigator, 2005–2006

*Ocular side effects of Cialis vs. Viagra vs. placebo*

Co-investigator, 2005–2006

*A Phase II, dose ranging, open-labeled, multi-center study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopia*

Co-investigator, 2005–2006

*Protein kinase C  $\beta$  inhibitor study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema*

Co-investigator, 2004–2010

*Anecortave Acetate Risk-Reduction Trial (AART)*

Co-investigator, 2004–2008

*An open-label study for the evaluation of tolerability of four dose levels of Cand5 administered by single intravitreal injection in patients with wet age-related macular degeneration*

Co-investigator, 2004–2007

*A Phase II randomized, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreal injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to central retinal vein occlusion (Eyetechnology 1011B)*

Co-investigator, 2004–2006

*A Phase II prospective, randomized, double-masked, sham controlled, dose-ranging, multi-center trial to assess the effect of pegaptanib sodium on fovea thickening in patients with exudative subfoveal age-related macular degeneration (Eyetechnology 1009)*

Co-investigator, 2004–2006

*A randomized, single-masked, multicenter, Phase 2 evaluation of the effect of photodynamic therapy using verteporfin (Visudyne<sup>®</sup> Therapy) in combination with intravitreal injection of either 0 mg, 1 mg, or 4 mg of triamcinolone acetonide in occult subfoveal and minimally classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD): Visudyne with Intravitreal Triamcinolone Acetonide (VisTA) Trial*

Co-investigator, 2004–2006

*Open label, non-comparative protocol for use of 0.3mg intravitreal Macugen injections every 6 weeks in patients with AMD (Eyetechnology 1010)*

Co-investigator, 2004–2005

*A phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFabv2 (ranibizumab) compared with verteporfin (Visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration*

Co-investigator, 2003–2006

*The Implantable Miniature Telescope (IMT™) in patients with central vision impairment associated with age-related macular degeneration or Stargardt's macular dystrophy*

Co-investigator, 2003–2005

*A randomized, double-masked, multi-center trial of the safety, tolerability and pharmacokinetics of 1 mg/eye and 3 mg/eye intravitreal injections of pegaptanib sodium (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks, in patients with exudative age-related macular degeneration (Eyeteck 1006)*

Co-investigator, 2002–2006

*Intravitreal Steroid Injection Studies (ISIS)*

Co-investigator, 2002–2006

*A Phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups, to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer), given every 6 weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema (CSME) involving the center of the macula (Eyeteck 1005)*

Co-investigator, 2002–2003

*Fluocinolone Acetonide in Diabetic Macular Edema (FAME 4) Study. A multicenter, randomized, masked, controlled study to evaluate the safety and efficacy of Retisert™, an intravitreal fluocinolone acetonide implant, in the treatment of patients with diabetic macular edema*

Co-investigator, 2001–2007

*Protein kinase C  $\beta$  inhibitor studies B7A-MC-MBCM. Diabetic Retinopathy Study 2*

Co-investigator, 2001–2006

*Phase II/III randomized, double-masked, controlled, dose-ranging, multicenter comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every six weeks for 54 weeks in patients with age-related macular degeneration*

Co-investigator, 2001–2005

*Oculex Study: A Phase 2 randomized, multicenter, dose-ranging, controlled, parallel-group trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS®) in the treatment of persistent macular edema*

Co-investigator, 2001–2003

*TTT4CNV Study: Transpupillary thermotherapy for subfoveal occult choroidal neovascularization in age-related macular degeneration*

Co-investigator, 2000–2004



*Phase IB open-label multicenter trial to establish the safety and pharmacokinetic profile of three consecutive injections of EYE001 (anti-VEGF pegylated aptamer) in patients with age-related macular degeneration without previous or concomitant photodynamic therapy with Visudyne™*

Co-investigator, 2000–2002

*Evaluation of efficacy and safety of a sub-Tenon's injection of anecortave acetate sterile suspension versus placebo in patients with exudative age-related macular degeneration (AMD) following treatment with photodynamic therapy (PDT) using Visudyne™*

Co-investigator, 2000–2001

*Open-label, multicenter, safety study of the treatment of predominantly classic choroidal neovascularization secondary to age-related macular degeneration using photodynamic therapy with verteporfin for injection*

Co-investigator, 1999–2000

#### *Verteporfin in Photodynamic Therapy Study*

Co-investigator, 1998–2003

*Protein kinase C  $\beta$  inhibitor studies B7A-MC-MBBK and B7A-MC-MBBM, Diabetic Macular Edema Study and Diabetic Retinopathy Study*

Co-investigator, 1998–2002

*Evaluation of safety and duration of efficacy of anecortave acetate sterile suspension versus placebo following a single sub-Tenon's injection for the inhibition of neovascularization in patients with exudative age-related macular degeneration*

Co-investigator, 1998–2001

*Study of the matrix metalloprotease inhibitor, AG3340, in patients with subfoveal choroidal neovascularization associated with age-related macular degeneration*

Co-investigator, 1998–2001

*Vitrace™ for Vitreous Hemorrhage Study*

Co-investigator, 1998–1999

*Age-related Macular Degeneration and Thalidomide Study*

*Treatment of Age-related Macular Degeneration with Photodynamic Therapy*

Co-investigator, 1996–2002

Co-investigator, 1996–2000

*Perfluron™ (perfluoro-n-octane) for use in the treatment of complicated retinal detachment*

Co-investigator, 1995–1996

*Oculon Study: Evaluation of the efficacy of OC-2 in the inhibition of cataract formation associated with vitrectomy surgery*

Principal Investigator, 1993–1994

*Hydrokinetic retinal manipulation using the viscous fluid perfluorocarbon  
perfluorophenanthrene study*

Co-investigator, 1993–1994

**SELECTED PRESENTATIONS AT LOCAL, NATIONAL, AND INTERNATIONAL MEETINGS AND SYMPOSIA**

1. Interesting retinal cases. Optometric Retinal Update. Akron, Ohio, November 1, 2018.
2. Interesting cases of vitreoretinal pathology. Community Doctors Education Program. Akron, Ohio, November 7, 2017.
3. ForeseeHome monitoring program for early detection of wet AMD. Optometric Retinal Update Seminar. Cleveland, Ohio, June 16, 2016.
4. Patient experience in a retinal office. Optometric Retinal Update Seminar. Akron, Ohio, April 6, 2016.
5. Update on treatment of rhegmatogenous retinal detachment. Optometric Retinal Update Seminar. Akron, Ohio, November 4, 2015.
6. Results of the Age-Related Eye Disease Study 2 (AREDS2). Optometric Retinal Update Seminar. Warren, Ohio, September 10, 2013.
7. Results of the Age-Related Eye Disease Study 2 (AREDS2). Optometric Retinal Update Seminar. Westlake, Ohio, June 18, 2013.
8. Retinal update on anti-VEGF therapy (with Drs. Coney, Miller, Rao, Schartman, and Zegarra). Ophthalmologists' Update Seminar. Vermilion, Ohio, December 20, 2012.
9. Lifestyle modifications to prevent the development & progression of macular degeneration. Advisory Council for Curing Blindness. Case Western Reserve University School of Medicine. Cleveland, Ohio, November 8, 2012.
10. Update of lifestyle modifications to treat patients with macular degeneration. Optometric Retinal Update Seminar. Youngstown, Ohio, September 20, 2012.
11. Retinal update on anti-VEGF therapy (with Drs. Coney, Miller, Rao, Schartman, and Zegarra). Ophthalmologists' Update Seminar. Vermilion, Ohio, August 12, 2012.
12. Posterior segment manifestations of ocular worm infestations. Optometric Retinal Update Seminar. Beachwood, Ohio, March 15, 2012.
13. Update of lifestyle modifications to treat patients with macular degeneration. Optometric Retinal Update Seminar. Westlake, Ohio, June 28, 2011.

14. Recent advances in the treatment of diabetic macular edema. Cleveland Ophthalmological Society. Cleveland, Ohio, October 12, 2010.
15. Advances in the treatment of diabetic macular edema. Optometric Retinal Update Seminar. Westlake, Ohio, August 19, 2010.
16. A patient's experience with a retinal specialist. Optometric Continuing Education Program and Open House. Lorain, Ohio, January 13, 2009.
17. Interesting retinal cases. Optometric Retinal Update Seminar. Westlake, Ohio, June 18, 2008.
18. Update on lifestyle and dietary modifications for patients with age-related macular degeneration (AMD). Optometric Retinal Update Seminar. Youngstown, Ohio, September 18, 2008.
19. Update on lifestyle and dietary modifications for patients with age-related macular degeneration (AMD). Optometric Retinal Update Seminar. Westlake, Ohio, July 15, 2008.
20. Interesting vitreoretinal cases. Optometric Retinal Update Seminar. Beachwood, Ohio, February 21, 2008.
21. Rhegmatogenous retinal detachment. Optometric Retinal Update Seminar. Youngstown, Ohio, September 5, 2007.
22. Rhegmatogenous retinal detachment. Optometric Retinal Update Seminar. Westlake, Ohio, July 17, 2007.
23. Modern treatment of rhegmatogenous retinal detachment. Optometric Retinal Update Seminar. Beachwood, Ohio, February 15, 2007.
24. Update on lifestyle and dietary modifications for patients with age-related macular degeneration. Optometric Retinal Update Seminar. Youngstown, Ohio, September 28, 2006.
25. Lifestyle and for people with age-related macular degeneration. Seminar on Age-related Macular Degeneration, in conjunction with Macula Vision Research Foundation SupportSight. Solon, Ohio, June 3, 2006.
26. Retinal detachment. Parma Community General Hospital Retinal Update. Parma, Ohio, March 21, 2006.
27. Lifestyle and dietary modifications for patients with age-related macular degeneration. Optometric Retinal Update Seminar. Beachwood, Ohio, February 9, 2006.

28. Nutrition and dietary modifications - can what I eat affect macular degeneration? Seminar on Nutrition and Macular Degeneration (joint presentation of Retina Associates of Cleveland and Macula Vision Research Foundation SupportSight). Middleburg Heights, Ohio, October 29, 2005.
29. Complications of vitrectomy. Cleveland Ophthalmological Society Meeting. Cleveland, Ohio, October 11, 2005.
30. An overview of macular degeneration. Optometric Retinal Update Seminar. Westlake, Ohio, August 11, 2005.
31. Macular degeneration. Lakewood Hospital Medical Grand Rounds. Lakewood, Ohio, April 2005.
32. Lifestyle & dietary modifications for patients with age-related macular degeneration. Optometric Retinal Update Seminar. Beachwood, Ohio, February 15, 2005.
33. Case report: blindness following glue embolization of a right temporal arteriovenous malformation. American Academy of Ophthalmology Meeting. New Orleans, Louisiana, October 2004.
34. Infectious endophthalmitis. Parma Community General Hospital. Parma, Ohio, October 5, 2004.
35. Posterior segment manifestations of ocular worm infestations. Optometric Retinal Update Seminar. Westlake, Ohio, July 29, 2004.
36. Case report: a patient with diabetes and cystoid macular edema. Cleveland Ophthalmological Society. Cleveland, Ohio, February 10, 2004.
37. Update on vitamins, nutrition, and age-related macular degeneration. Optometric Retinal Update Seminar. Westlake, Ohio, August 12, 2003.
38. Vitamins, nutrition, and age-related macular degeneration. Optometric Retinal Update Seminar. Beachwood, Ohio, February 20, 2003.
39. Vitamins, nutrition, and age-related macular degeneration. Optometric Retinal Update. Cleveland, Ohio, August 2003.
40. Posterior vitreous separation, retinal tears and detachments. Optometric Retinal Update. Cleveland, Ohio, February 26, 2002.
41. Diffuse unilateral subacute neuroretinitis. Cleveland Ophthalmological Society. Cleveland, Ohio, February 12, 2002.
42. Sheen retinal dystrophy (co-authors: Polk TD, Gass JDM, Green WR, Johnson MW). Cleveland Ophthalmological Society. Cleveland, Ohio, February 6, 1996.

43. Blindness and diabetes. Hillcrest Hospital. Diabetes Educational Update: From Head to Toe. June 7, 1995, Cleveland, Ohio.
44. Vitreous surgery for the vitreomacular traction syndrome (co-author: Rice TA). The Macula Society Seventeenth Annual Meeting, February 24, 1994, Rancho Mirage, California. The Vitreous Society Annual Meeting, 1994, Aspen, Colorado. The Retina Society Annual Meeting, 1994, Williamsburg, Virginia.
45. Ohio Ophthalmological Society. June 6, 1993, Columbus, Ohio.
46. The aging eye. Lakewood Hospital Health Talks. August 26, 1992, Lakewood, Ohio.
47. Neovascular glaucoma (co-author: Lamping KA). University Hospitals, Ophthalmology Grand Rounds. June 2, 1992, Cleveland, Ohio.
48. Vitreous surgery for idiopathic macular holes. University Hospitals, Department of Ophthalmology Faculty and Alumni Symposium. May 29, 1992, Cleveland, Ohio.
49. Ohio Ophthalmological Society. May 9, 1992, Columbus, Ohio.
50. Diabetes and your eyes. Euclid Hospital Diabetes Recheck Clinic. May 6, 1992, Cleveland, Ohio.
51. Macular degeneration. Lakewood Hospital. March 31, 1992, Lakewood, Ohio.
52. Diabetes and your eyes. Hillcrest Hospital Diabetes Education Program. November 7, 1991, Cleveland, Ohio.
53. Acetazolamide for cystoid macular edema from diabetic maculopathy. Cleveland Ophthalmological Society. October 1, 1991, Cleveland, Ohio.
54. Holes, tears, and lattice degeneration—this year's management. Case Western Reserve University School of Medicine Continuing Education in Ophthalmology, Current Concepts in Retinal Diseases. September 22, 1989, Cleveland, Ohio.
55. Corneal pathology, Part II. St. Luke's Hospital. May 1989, Cleveland, Ohio.
56. Diabetic retinopathy. Healthlines, Cleveland Academy of Medicine radio program, WCLV. January and February 1989, Cleveland, Ohio.
57. The pupil. Greater Cleveland Ophthalmic Medical Assistants and Technicians Society. November 1988, Cleveland, Ohio.
58. Calcium oxalate retinopathy associated with methoxyflurane abuse (co-authors: Roth AS, Levine MR). American Academy of Ophthalmology Meeting, 1987.
59. Indications for ultrasonography. Kresge Eye Institute, Wayne State University School of Medicine. Update in Ophthalmic Ultrasound. Detroit, Michigan, 1986.

60. Pre-Academy Fluorescein Angiography Club, American Academy of Ophthalmology Meeting, 1985–2005.
61. Management of posterior segment trauma. University Hospitals of Cleveland, Cleveland, Ohio, November 1985.
62. Fluorescein angiography study of idiopathic epiretinal membranes (coauthors: Wesberry Jr J, Singerman LJ, Rice TA). Wilmer (Johns Hopkins) Residents Association Annual Meeting, 1985. Ohio Ophthalmological Society, 1987.
63. Diabetic retinopathy. Fairview General Hospital, Cleveland, Ohio, February 1986.
64. Red krypton and argon laser photocoagulation in central serous chorioretinopathy (co-authors: Singerman LJ, Rice TA). Association for Research in Vision and Ophthalmology Annual Spring Meeting, 1985. Ohio Ophthalmological Society, 1986.
65. New concepts in central serous retinopathy (co-authors: Singerman LJ, Rice TA, Passloff R). Wilmer (Johns Hopkins) Residents Association Annual Meeting, 1984.
66. Preoperative and surgical prognostic risk factors in successful diabetic vitrectomies (co-authors: Michels RG, Rice TA, Auer C). American Academy of Ophthalmology Meeting, 1983.
67. Diabetic vitrectomy and postoperative vitreous hemorrhage (co-authors: Michels RG, Rice TA, Auer C). Wilmer (Johns Hopkins) Residents Association Annual Meeting, 1983.
68. Specular microscopy of Schnyder central crystalline dystrophy of the cornea (co-author: Hirst LW). International Congress of Ophthalmology Meeting, 1982.
69. The lens and diabetic vitrectomy (co-authors: Rice TA, Michels RG). Wilmer (Johns Hopkins) Residents Association Annual Meeting, 1982. American Academy of Ophthalmology Meeting, 1982.
70. Macular coloboma and congenital cytomegalovirus infection (co-authors: Jabs DA, Welch RB). American Academy of Ophthalmology Meeting, 1981.
71. Acute posterior vitreous detachments and their complications (co-author: Welch RB). Wilmer (Johns Hopkins) Residents Association Annual Meeting, 1981. Association for Research in Vision and Ophthalmology Annual Spring Meeting, 1981.
72. Clinical case report of familial giant cell arteritis. Wilmer (Johns Hopkins) Residents Association Annual Meeting, 1979.

## PUBLICATIONS

*Journal Articles*

1. Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Elliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial. *Ophthalmology*. 2018 Oct 4. pii: S0161-6420(18)31427-1. doi: 10.1016/j.ophtha.2018.09.041. [Epub ahead of print]
2. Yu JJ, Agrón E, Clemons TE, Domalpally A, van Asten F, Keenan TD, Cukras C, Chew EY; Age-Related Eye Disease Study 2 Research Group. Natural history of drusenoid pigment epithelial detachment associated with age-related macular degeneration: Age-Related Eye Disease Study 2 report no. 17. *Ophthalmology*. 2018 Aug 22. pii: S0161-6420(18)31752-4. doi: 10.1016/j.ophtha.2018.08.017. [Epub ahead of print]
3. Keenan TD, Agrón E, Domalpally A, Clemons TE, van Asten F, Wong WT, Danis RG, Sadda S, Rosenfeld PJ, Klein ML, Ratnapriya R, Swaroop A, Ferris FL 3rd, Chew EY; AREDS2 Research Group. Progression of geographic atrophy in age-related macular degeneration: AREDS2 Report Number 16. *Ophthalmology*. 2018;125:1913-1928.
4. Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC; Diabetic Retinopathy Clinical Research Network. Plasma vascular endothelial growth factor concentrations after intravitreal anti-vascular endothelial growth factor therapy for diabetic macular edema. *Ophthalmology*. 2018;125:1054-1063.
5. Purnell JQ, Braffett BH, Zinman B, Gubitosi-Klug RA, Sivitz W, Bantle JP, Ziegler G, Cleary PA, Brunzell JD; DCCT/EDIC Research Group. Impact of excessive weight gain on cardiovascular outcomes in Type 1 Diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. *Diabetes Care*. 2017;40:1756-1762.
6. DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM. Frequency of evidence-based screening for retinopathy in Type 1 diabetes. *N Engl J Med*. 2017 Apr 20;376:1507-1516.
7. Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD; DCCT/EDIC Research Group, Natarajan R. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. *Proc Natl Acad Sci U S A*. 2016;113(21):E3002-11.

8. Lenherr SM, Clemens JQ, Braffett BH, Cleary PA, Dunn RL, Hotaling JM, Jacobson AM, Kim C, Herman W, Brown JS, Wessells H, Sarma AV; DCCT/EDIC Research Group. Glycemic control and urinary tract infections in women with type 1 diabetes: Results from the DCCT/EDIC. *J Urol*. 2016;196:1129-1135.
9. AREDS2 Research Group, Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Sperduto RD, Ferris FL 3rd, Chew EY. The association of statin use with cataract progression and cataract surgery: AREDS2 Report Number 8. *Ophthalmology*. 2016;123:916-917.
10. Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. *Ophthalmology*. 2016;123:865-875.
11. Shah N, Maguire MG, Martin DF, Shaffer J, Ying GS, Grunwald JE, Toth CA, Jaffe GJ, Daniel E; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Angiographic cystoid macular edema and outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology*. 2016;123:858-864.
12. Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME; Diabetic Retinopathy Clinical Research Network. Persistent macular thickening after ranibizumab treatment. *JAMA Ophthalmol*. 2016;134:278-285.
13. Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW; Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. *JAMA Ophthalmol*. 2016 Feb;134:127-134.
14. Daniel E, Shaffer J, Ying GS, Grunwald JE, Martin DF, Jaffe GJ, Maguire MG; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology*. 2016;123:609-616.
15. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Panretinal photocoagulation vs intravitreal ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. *JAMA*. 2015 Nov 13:1-11.



16. Aref AA, Scott IU, Oden NL, Ip MS, Blodi BA, VanVeldhuisen PC; SCORE Study Investigator Group. Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE Study Report 15. *JAMA Ophthalmol.* 2015;133:1022-1029.
17. Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA; Diabetic Retinopathy Clinical Research Network. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycemic control: a randomized clinical trial. *JAMA Ophthalmol.* 2015;133:888-896.
18. Eny KM, Orchard TJ, Miller RG, Maynard J, Grant DM, Costacou T, Cleary PA, Braffett BH, Paterson AD; DCCT/EDIC Research Group. Caffeine consumption contributes to skin intrinsic fluorescence in type 1 Diabetes. *Diabetes Technol Ther.* 2015;17:726-734.
19. Bressler SB, Almkhatar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M; Diabetic Retinopathy Clinical Research Network Investigators. Repeated intravitreal ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. *JAMA Ophthalmol* 2015;133:589-597.
20. Willoughby AS, Ying GS, Toth CA, Maguire MG, Burns RE, Grunwald JE, Daniel E, Jaffe GJ; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Subretinal hyperreflective material in the Comparison of Age-Related Macular Degeneration Treatments Trials. *Ophthalmology* 2015;122:1846-1853.
21. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med* 2015 Mar 26;372:1193-1203.
22. Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, et al; Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). *Ophthalmology* 2015;122:391-398.
23. Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, Singerman L, Schwartz SD, Peachey NS, Bird AC; MacTel-CNTF Research Group. Ciliary neurotrophic factor (CNTF) for macular telangiectasia Type 2 (MacTel): Results from a phase I safety trial. *Am J Ophthalmol* 2015;159:659-666.

24. Simpson CL, Wojciechowski R, Oexle K, Murgia F, Portas L, Li X, Verhoeven VJ, et al; DCCT/EDIC Research Group. Genome-wide meta-analysis of myopia and hyperopia provides evidence for replication of 11 loci. *PLoS One* 2014 Sep 18;9(9):e107110. doi: 10.1371/journal.pone.0107110. eCollection 2014.
25. Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group. Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2014 Oct;121(10):1956-1965.
26. Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group. VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT). *JAMA Ophthalmol* 2014;132:521-527.
27. Maguire MG, Daniel E, Shah AR, Grunwald JE, et al; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group). Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2013;120:2035-2041.
28. Jaffe GJ, Martin DF, Toth CA, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. *Ophthalmology* 2013;120:1860-1870.
29. Cheng CY, Schache M, Ikram MK, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions, and Complications Research Group. Nine loci for ocular axial length identified through genome-wide association studies, including shared loci with refractive error. *Am J Hum Genet* 2013;93:264-277.
30. Bressler SB, Qin H, Melia M, et al; Diabetic Retinopathy Clinical Research Network. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. *JAMA Ophthalmol* 2013;131:1033-1040.
31. Danis RP, Domalpally A, Chew EY, et al; AREDS2 Study Group. Methods and reproducibility of grading optimized digital color fundus photographs in the Age-Related Eye Disease Study 2 (AREDS2 Report Number 2). *Invest Ophthalmol Vis Sci* 2013;54:4548-4554.
32. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. *JAMA* 2013 May 15;309:2005-2015.
33. Verhoeven VJ, Hysi PG, Wojciechowski R, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC)

- Research Group, Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. *Nat Genet* 2013;45:314-318.
34. Hagstrom SA, Ying GS, Pauer GJ, et al; Comparison of AMD Treatments Trials Research Group. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). *Ophthalmology* 2013;120:593-599.
  35. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. *JAMA Ophthalmol* 2013;131:283-293.
  36. Niskopoulou M, Balaskas K, Leung I, Sallo FB, Clemons TE, Bird AC, Peto T; MacTel Study group. Is indocyanine green angiography useful for the diagnosis of macular telangiectasia type 2? *Br J Ophthalmol* 2013;97:946-948.
  37. Ying GS, Huang J, Maguire MG, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. *Ophthalmology* 2013;120:122-129.
  38. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Wang JJ, Mitchell P, Ramdas WD, Vingerling JR, Macular Telangiectasia Project Research Group. Medical Characteristics of Patients with Macular Telangiectasia Type 2 (MacTel Type 2) MacTel Project Report No. 3. *Ophthalmic Epidemiology* 2013; 20:109-113.
  39. Sallo FB, Peto T, Egan C, Wolf-Schnurrbusch UE, Clemons TE, Gillies MC, Pauleikhoff D, Rubin GS, Chew EY, Bird AC; MacTel Study Group. The IS/OS junction layer in the natural history of type 2 idiopathic macular telangiectasia. *Invest Ophthalmol Vis Sci* 2012;53:7889-7895
  40. Sallo FB, Peto T, Egan C, Wolf-Schnurrbusch UE, Clemons TE, Gillies MC, Pauleikhoff D, Rubin GS, Chew EY, Bird AC; MacTel Study Group. "En face" OCT imaging of the IS/OS junction line in type 2 idiopathic macular telangiectasia. *Invest Ophthalmol Vis Sci* 2012;53:6145-6152.
  41. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, Glassman AR, Maturi RK, Melia M. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology* 2012;119:2312-2318.
  42. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. *Ophthalmology* 2012;119:1388-1398.

43. Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group, Li J. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. *Ophthalmology* 2011;118:2453-2460.
44. Sallo FB, Leung I, Chung M, Wolf-Schnurrbusch UE, Dubra A, Williams DR, Clemons T, Pauleikhoff D, Bird AC, Peto T; MacTel Study Group. Retinal crystals in type 2 idiopathic macular telangiectasia. *Ophthalmology* 2011;118:2461-2467.
45. Chan CK, Ip MS, VanVeldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA; SCORE Study Investigator Group. SCORE Study Report #11. Incidences of neovascular events in eyes with retinal vein occlusion. *Ophthalmology* 2011;118:1364-1372.
46. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration.. *N Engl J Med* 2011 May 19;364:1897-1908.
47. Diabetic Retinopathy Clinical Research Network; Writing Committee, Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology* 2011;118:609-614.
48. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, Bressler SB, Ferris FL 3rd, Gupta SK, Haller JA, Lazarus HS, Qin H. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research Network. *Retina* 2010;30:1488-1495.
49. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology* 2010;117:1134-1146.
50. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. *Ophthalmology*. 2010;117:1064-1070.
51. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, Harrington MW; MacTel Research Group. Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2. *Ophthalmic Epidemiol* 2010;17:66-73.
52. Diabetic Retinopathy Clinical Research Network. The course of response to focal/grid photocoagulation for diabetic macular edema. *Retina* 2009 Nov-Dec;29:1436-1443.

53. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. *Am J Ophthalmol* 2009;148:725-732.
54. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.
55. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.
56. Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Figueroa M, Antoszyk A, Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770–1777.
57. Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett ME, Kollman C, Li HK, Qin H, Scott IU; Diabetic Retinopathy Clinical Research Network Study Group. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. *Invest Ophthalmol Vis Sci* 2008;49:1745-1752.
58. Ying GS, Maguire MG, Alexander J, Martin RW, Antoszyk AN; Complications of Age-related Macular Degeneration Prevention Trial Research Group. Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial. *Arch Ophthalmol* 2009;127:1147-1151.
59. Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H; Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology* 2008;115:1366-71, 1371.e1.
60. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H; Diabetic Retinopathy Clinical Research Network Study Group. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. *Retina* 2008;28:36-40.

61. Submacular Surgery Trials Research Group, Mann AL, Bressler SB, Hawkins BS, Holekamp N, Bressler NM. Comparison of methods to identify incident cataract in eyes of patients with neovascular maculopathy: Submacular Surgery Trials Report No. 18. *Ophthalmology* 2008;115:127-133.
62. Submacular Surgery Trials Research Group, Solomon SD, Jefferys JL, Hawkins BS, Bressler NM. Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. *Arch Ophthalmol* 2007;125:1323-1330.
63. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. *Ophthalmology* 2007;114:1860-1867.
64. Macugen AMD Study Group. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology* 2007;114:1702-1712.
65. Diabetic Retinopathy Clinical Research Network. Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. *Ophthalmology* 2007;114:1190-1196.
66. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. *Ophthalmology* 2007;114:525-536.
67. Diabetic Retinopathy Clinical Research Network. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. *Ophthalmology*. 2007;114:15201-1525.
68. Diabetic Retinopathy Clinical Research Network. Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. *Arch Ophthalmol* 2007;125:469-480.
69. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch Ophthalmol* 2007;125:309-317.
70. Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. *Surv Ophthalmol* 2007;52 Suppl 1:S79-90.
71. Complications of Age-related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: The Complications of Age-Related Macular Degeneration Prevention Trial. *Ophthalmology* 2006;113:1974-1986.

72. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 2006;355:1432-1444.
73. Submacular Surgery Trials Research Group. Guidelines for interpreting retinal photographs and coding findings in the Submacular Surgery Trials (SST). SST report no. 8. *Retina* 2005;25:253-268.
74. Submacular Surgery Trials Research Group. Histopathological and ultrasound features of surgically excised subfoveal choroidal neovascular lesions. SST report no. 7. *Arch Ophthalmol* 2005;123:914-921.
75. Submacular Surgery Trials Research Group. Health-related quality of life among patients with ocular histoplasmosis or idiopathic choroidal neovascularization at enrollment in a randomized trial of submacular surgery. SST report no. 5. *Arch Ophthalmol* 2005;123:78-88.
76. Submacular Surgery Trials Research Group. Effect of order of administration of health-related quality of life instruments on responses. SST report no. 3. *Qual Life Res* 2005;14:493-500.
77. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004 Dec 30;351:2805-2816.
78. Hawkins BS, Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. *Am J Ophthalmol* 2004;138:936-951.
79. Submacular Surgery Trials Research Group. Patients' perceptions of the value of current vision: assessment of preference values among patients with subfoveal choroidal neovascularization--The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6. *Arch Ophthalmol* 2004;122:1856-1867
80. Submacular Surgery Trials Research Group. Surgery for predominantly hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Quality-of-life findings. SST report no. 14. *Ophthalmology* 2004;111:2007-2014.
81. Submacular Surgery Trials Research Group. Surgery for predominantly hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findings. SST report no. 13. *Ophthalmology* 2004;111:1993-2006.
82. Submacular Surgery Trials Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Quality-of-life findings. SST report no. 12. *Ophthalmology* 2004;111:1981-1992.

83. Submacular Surgery Trials Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings. SST report no. 11. *Ophthalmology* 2004;111:1967-1980.
84. Submacular Surgery Trials Research Group. Surgical removal versus observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial. SST Group H Trial. SST report no. 10. *Arch Ophthalmol* 2004;122:1616-1628.
85. Submacular Surgery Trials Research Group. Surgical removal versus observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: SST Group H Trial. SST Report No. 9. *Arch Ophthalmol* 2004;122:1597-1611.
86. Maguire M; Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 2004;111:1307-1316.
87. Collaborative Ocular Melanoma Study Group. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS Report No. 22. *Ophthalmology* 2004;111:966-976.
88. Submacular Surgery Trials Research Group. Clinical trial performance of community-based compared with university-based practices: Lessons from the Submacular Surgery Trials. SST report no. 2. *Arch Ophthalmol* 2004;122:857-863.
89. Bressler SB, Pieramici DJ, Koester JM, Bressler NM for the TAP Study Group. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management - TAP report No. 6. *Arch Ophthalmol* 2004 Mar;122:325-329.
90. Submacular Surgery Trials Research Group. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at time of enrollment in randomized trials of submacular surgery. SST report no. 4. *Am J Ophthalmol* 2004;138:91-108.
91. Complications of Age-related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design, and methodology. *Clinical Trials* 2004; 1:91-107.
92. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular



- Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report no. 4. *Retina* 2004;24:1-12.
93. Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS Report No. 21. *Arch Ophthalmol* 2003;121:1163-1171.
  94. Collaborative Ocular Melanoma Study Group. Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS Report No. 20. *Arch Ophthalmol* 2003;121:1156-1162.
  95. Reynolds SM, Cella D, Murray TG, Hovland KR, Hayman JA, Mangione CM, The Collaborative Ocular Melanoma Study-Quality of Life Study Group. Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS report No. 2. *Arch Ophthalmol* 2003;121:1010-1020.
  96. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology* 2003;110:2372-2383.
  97. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, Lim JJ, Menchini U, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld P, Schachat AP, Schmidt-Erfurth U, Sickenberg M, Singerman LJ, Slakter JS, Strong HA, Virgili G, Williams GA; Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP Report No. 3. *Ophthalmology* 2003;110:667-673.
  98. The Submacular Surgery Trials Research Group. Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization - SST Report No. 1. *Arch Ophthalmol* 2003;121:531-539.
  99. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P; The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. *Retina* 2003;23:14-23.

100. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE; Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. *Am J Ophthalmol* 2003;136:47-54.
101. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19. *Ophthalmology* 2002;109:2197-2206.
102. Rubin GS, Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the Treatment of Age-related macular degeneration with Photodynamic therapy (TAP) Investigation - TAP Report No. 4. *Retina* 2002;22:536-544.
103. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration. Additional information regarding baseline lesion composition's impact on vision outcomes - TAP Report No. 3. *Arch Ophthalmol* 2002;120:1443-1454.
104. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials - TAP report No. 5. *Arch Ophthalmol* 2002;120:1307-1314.
105. Collaborative Ocular Melanoma Study Group. Sociodemographic and clinical predictors of participation in two randomized trials: Findings from the Collaborative Ocular Melanoma Study. COMS Report No. 7. *Controlled Clin Trials* 2001;22:526-537.
106. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma, III. Initial mortality findings. COMS Report No. 18. *Arch Ophthalmol* 2001;119:969-982.
107. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for choroidal melanoma, II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17. *Arch Ophthalmol* 2001;119:951-965.
108. Grostern RJ, Slusker Shternfeld I, Bacus SS, Gilchrist K, Zimbric ML, Albert DM; Collaborative Ocular Melanoma Study Group. Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes. *Am J Ophthalmol* 2001;131:788-791.

109. The Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS Report No. 16. *Ophthalmology* 2001;108:348-366.
110. The Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15. *Arch Ophthalmol* 2001;119:670-676.
111. Doft BH, Wisniewski SR, Kelsey SF, Fitzgerald SG; Endophthalmitis Vitrectomy Study Group. Diabetes and postoperative endophthalmitis in the endophthalmitis vitrectomy study. *Arch Ophthalmol* 2001;119:650-656.
112. Moy CS, Albert DM, Diener-West M, McCaffrey LD, Scully RE, Willson JK; The Collaborative Ocular Melanoma Study Group, prepared by COMS Mortality Coding Committee. Cause-specific mortality coding. Methods in the Collaborative Ocular Melanoma Study. COMS Report No. 14. *Control Clin Trials* 2001;22:248-262.
113. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Verteporfin in Photodynamic Therapy Report 2. *Am J Ophthalmol* 2001;131:541-560.
114. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report #2. *Arch Ophthalmol* 2001;119:198-207.
115. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: One-year results of a randomized clinical trial. VIP report #1. *Ophthalmology* 2001;108:841-852.
116. Submacular Surgery Trials Pilot Study Investigators. Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration. II. Quality of life outcomes. Submacular Surgery Trials Pilot Study Report Number 2. *Am J Ophthalmol* 2000;130:408-418.
117. Submacular Surgery Trials Pilot Study Investigators. Submacular Surgery Trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration. I: Ophthalmic outcomes Submacular Surgery Trials Pilot Study Report Number 1. *Am J Ophthalmol* 2000;130:387-407.

118. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP Report 1. *Arch Ophthalmol* 1999; 117:1329-1345.
119. COMS Quality of Life Study Group. Quality of life assessment in the collaborative ocular melanoma study: design and methods. COMS-QOLS Report No. 1. *Ophthalmic Epidemiol* 6:5-17, 1999.
120. Collaborative Ocular Melanoma Study Group. Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study. COMS Report No. 12. *J Ophth Nurs Technol* Part I 18:143-149, Part II 18:219-232, 1999.
121. Parnes RE, Zakov ZN, Novak MA, Rice TA. Vitrectomy in patients with decreased visual acuity secondary to asteroid hyalosis. *Am J Ophthalmol* 1998;125:703-704.
122. Choroidal Neovascularization Prevention Trial Research Group. Choroidal neovascularization in the choroidal neovascularization prevention trial. *Ophthalmology* 1998;105:1364-1372.
123. Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III. Local complications and observations following enucleation. COMS Report No. 11. *Am J Ophthalmol* 126: 362-372, 1998.
124. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II. Initial mortality findings. COMS Report No. 10. *Am J Ophthalmol* 125:779-796, 1998.
125. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. I. Characteristics of patients enrolled and not enrolled. COMS Report No. 9. *Am J Ophthalmol* 125:767-778, 1998.
126. The Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6. *Am J Ophthalmol* 125:745-766, 1998.
127. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. *Ophthalmology* 1998;105:11-23.
128. Polk TD, Gass JD, Green WR, Novak MA, Johnson MW. Familial internal limiting membrane dystrophy. A new sheen retinal dystrophy. *Arch Ophthalmol* 1997;15:878-885.

129. Grossniklaus HE, Albert DM, Green WR, Conway BP, Hovland KR for the Collaborative Ocular Melanoma Study Group. Clear cell differentiation in choroidal melanoma. COMS report no. 8. *Arch Ophthalmol* 1997;115:894-898.
130. The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma. COMS Report No. 5. *Arch Ophthalmol* 1997;115:1537-1544.
131. The Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS Report No. 4. *Arch Ophthalmol* 1997;115:886-893.
132. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Arch Ophthalmol* 1997; 115:741-747.
133. Dean JM, Novak MA, Chan CC, Green WR. Tumor detachments of the retinal pigment epithelium in ocular/central nervous system lymphoma. *Retina* 1996;16:47-56.
134. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. *Arch Ophthalmol* 1996; 114:677-688.
135. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. *Arch Ophthalmol* 1995;113:1479-1496.
136. Macular Photocoagulation Study Group. The influence of treatment extent on the visual acuity of eyes treated with Krypton laser for juxtafoveal choroidal neovascularization. *Arch Ophthalmol* 1995; 113:190-194.
137. Macular Photocoagulation Study Group. Laser photocoagulation for neovascular lesions nasal to the fovea. Results from clinical trials for lesions secondary to ocular histoplasmosis or idiopathic causes. *Arch Ophthalmol* 1995; 113:56-61.
138. Novak MA. Vitrectomy for epiretinal membranes. *Sem Ophthalmol* 1994; 9:29-46.
139. Macular Photocoagulation Study Group. Evaluation of argon green vs. krypton red laser for photocoagulation of subfoveal choroidal neovascularization in the Macular Photocoagulation Study. *Arch Ophthalmol* 1994;112:1176-1184.
140. Macular Photocoagulation Study Group. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. *Arch Ophthalmol* 1994;112:500-509.

141. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization. *Arch Ophthalmol* 1994;112:489-499.
142. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. *Arch Ophthalmol* 1994;112:480-488.
143. Krypton Argon Regression of Neovascularization Study Group. Randomized comparison of krypton versus argon scatter photocoagulation for diabetic disc neovascularization. The Krypton Argon Regression of Neovascularization Study report number 1. *Ophthalmology* 1993; 100:1655-1664.
144. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. *Controlled Clin Trials* 1993;14:362-391,
145. Collaborative Ocular Melanoma Study Group. Complications of enucleation surgery. COMS Report No. 2. In Franklin RM (ed). *Proceedings of the Symposium on Retina and Vitreous, New Orleans Academy of Ophthalmology*. New York: Kugler Publications, 1993, pp 181-190.
146. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. *Arch Ophthalmol* 1993;111:1200-1209.
147. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. *Arch Ophthalmol* 1993;111:1189-1199.
148. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: Guidelines for evaluation and treatment in the Macular Photocoagulation Study. *Arch Ophthalmol* 1991; 109:1242-1257
149. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration Results of a randomized clinical trial. *Arch Ophthalmol* 1991; 109:1232-1241.
150. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. *Arch Ophthalmol* 1991; 109:1219-1230.
151. Macular Photocoagulation Study Group (MA Novak on Writing Committee). Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. *Arch Ophthalmol* 1991; 109:1109-1114.

152. Fine SL, Maguire MG, Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. *Arch Ophthalmol* 1991; 109:614-615.
153. Marcus DM, Minkovitz JB, Wardwell SD, Albert DM for the Collaborative Ocular Melanoma Study Group. The value of nucleolar organizer regions in uveal melanoma. *Am J Ophthalmol* 110:527-534, 1990.
154. Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS Report No. 1. *Arch Ophthalmol* 108:1268-1273, 1990.
155. Novak MA, Singerman LJ. Commentary on Newsome DA, The boggy macula: a medical approach. *Clin Dec Ophthalmol* 1989; 14:12-13.
156. Straatsma BR, Fine SL, Earle JD, Hawkins BS, Diener-West M, McLaughlin JA, Collaborative Ocular Melanoma Study Research Group. Enucleation versus plaque irradiation for choroidal melanoma. *Ophthalmology* 95:1000-1004, 1988.
157. Roth AS, Novak MA, Levine MR. Calcium oxalate retinopathy associated with methoxyflurane abuse. *Retina* 1988;8:230-236.
158. Novak MA, Singerman LJ. What are the current methods of managing central serous choroidopathy? Is laser treatment indicated and, if so, when? *Ophthalmic Practice* 1988;6:170-171.
159. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis. *Arch Ophthalmol* 1987;105:1499-1507, 1987.
160. Novak MA, Singerman LJ, Rice TA. Krypton and argon laser photocoagulation for central serous chorioretinopathy. *Retina* 1987;7:162-169.
161. Novak MA; Green WR; Miller NR. Familial giant cell arteritis [letter]. *J Clin Neuro Ophthalmol* 1986;6:126.
162. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: three-year results from randomized clinical trials. *Arch Ophthalmol* 1986;104:694-701.
163. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. *Arch Ophthalmol* 1986;104:503-512.
164. Macular Photocoagulation Study Group. Changing the protocol: a case report from the Macular Photocoagulation Study. *Controlled Clin Trials* 1984; 5:203-216.

165. Macular Photocoagulation Study Group. Age-related macular degeneration. *Am J Ophthalmol* 1984;98:376.
166. Novak MA, Rice TA, Michels RG, Auer C. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. *Ophthalmology* 1984;91:1485-1489.
167. Novak MA, Rice TA, Michels RG, Auer C. The crystalline lens after vitrectomy for diabetic retinopathy. *Ophthalmology* 1984;91:1480-1484.
168. Novak MA, Green WR, Miller NR. Ophthalmological manifestations: A case of familial giant cell arteritis. *Maryland State Medical Journal* 1984;33:817-820.
169. Gilbert MG, Novak MA. Successful treatment of postoperative Candida endophthalmitis in an eye with an intraocular lens implant. *Am J Ophthalmol* 1984;97:593-595.
170. Novak MA, Welch RB. Complications of acute symptomatic posterior vitreous detachment. *Am J Ophthalmol* 1984;97:308-314.
171. Hirst LW, Werblin T, Novak MA, Green WR, Pollack I. Drug-induced cicatrizing conjunctivitis simulating ocular pemphigoid. *Cornea* 1982;1:121.
172. Novak MA, Welch RB. Complications of acute posterior vitreous detachment. *Invest Ophthalmol Vis Sci* (Suppl) 1981;20:235.
173. Novak MA, Green WR. Malakoplakia of the orbit. *Invest Ophthalmol Vis Sci* (Suppl) 1980;19:122.
174. Naff GB, Hedrick SW, Ratnoff WD, Novak MA, Smith MC, Steiner C, Todd EW. The rabbit properdin system. I. Identification of a new factor and purification of rabbit properdin. *J Immunol* 1980;124:2625-2631.
175. Smith MC, Steiner C, Novak MA, Todd EW, Naff GB. Studies on the mechanism of action and purification of Factor X, an early acting component of the properdin system. *J Immunol* 1976;116:1750.
176. Naff GB, Todd EW, Novak MA, Ratnoff WD. The rabbit properdin system: Identification of two new early acting components and purification of rabbit properdin. *Fed Proc* 1975;34:955.

### **Book Chapters**

1. Pendergast SD, Zakov ZN, Novak MA. Lasers in vitreous surgery. In Singerman LJ, Coscas G (eds). *Current Techniques in Ophthalmic Laser Surgery*. Philadelphia: Current Medicine, pp 153-164, 1999.



2. Novak MA, Rice TA. The realities of endophthalmitis. In: Weinstock FJ (ed). *Management and Care of the Cataract Patient*. Boston: Blackwell Scientific Publications, Inc, 1992.
3. Singerman LJ, Novak MA. Subretinal neovascularization. In: Yannuzzi LA (ed). *Laser Photocoagulation of the Macula*. Philadelphia: JB Lippincott Company, 1989, pp 27-46.
4. Novak MA, Hirst LW. Specular microscopy of Schnyder central crystalline dystrophy of the cornea. In: Henkind P (ed). *Acta: XXIV International Congress of Ophthalmology*. Philadelphia: JB Lippincott Company, 1983, pp 286-289.

### **Posters**

1. Rostamizadeh M, Abdelaziz M, Patel A, Moarefi M, Miller D, Coney J, Novak M, Rao L, Pendergast S, Singerman L. Incidence of endophthalmitis in various anti-VEGF treatments. Scientific Poster 5025/ B0231, Association for Research in Vision and Ophthalmology Annual Meeting, May 2016.
2. Singerman LJ, Himmelman DR, Singerman B, Thomas A, Newman L, Coney JM, Schartman JP, Novak MA. Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion. Program#/Poster# 5466/A662. Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, Florida, May 2012.